483 related articles for article (PubMed ID: 30456528)
1. Severe necrotizing myositis associated with long term anti-neoplastic efficacy following nivolumab plus ipilimumab combination therapy.
Tauber M; Cohen R; Laly P; Josselin L; André T; Mekinian A
Clin Rheumatol; 2019 Feb; 38(2):601-602. PubMed ID: 30456528
[TBL] [Abstract][Full Text] [Related]
2. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
Overman MJ; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Svrcek M; Moss RA; Ledeine JM; Cao ZA; Kamble S; Kopetz S; André T
J Clin Oncol; 2018 Mar; 36(8):773-779. PubMed ID: 29355075
[TBL] [Abstract][Full Text] [Related]
3. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
Lenz HJ; Van Cutsem E; Luisa Limon M; Wong KYM; Hendlisz A; Aglietta M; García-Alfonso P; Neyns B; Luppi G; Cardin DB; Dragovich T; Shah U; Abdullaev S; Gricar J; Ledeine JM; Overman MJ; Lonardi S
J Clin Oncol; 2022 Jan; 40(2):161-170. PubMed ID: 34637336
[TBL] [Abstract][Full Text] [Related]
4. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.
Morse MA; Overman MJ; Hartman L; Khoukaz T; Brutcher E; Lenz HJ; Atasoy A; Shangguan T; Zhao H; El-Rayes B
Oncologist; 2019 Nov; 24(11):1453-1461. PubMed ID: 31147488
[TBL] [Abstract][Full Text] [Related]
5. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study.
Cohen R; Bennouna J; Meurisse A; Tournigand C; De La Fouchardière C; Tougeron D; Borg C; Mazard T; Chibaudel B; Garcia-Larnicol ML; Svrcek M; Vernerey D; Menu Y; André T
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33148693
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.
André T; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Abdullaev S; Memaj A; Lei M; Dixon M; Kopetz S; Overman MJ
Ann Oncol; 2022 Oct; 33(10):1052-1060. PubMed ID: 35764271
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
D'Angelo SP; Mahoney MR; Van Tine BA; Atkins J; Milhem MM; Jahagirdar BN; Antonescu CR; Horvath E; Tap WD; Schwartz GK; Streicher H
Lancet Oncol; 2018 Mar; 19(3):416-426. PubMed ID: 29370992
[TBL] [Abstract][Full Text] [Related]
8. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and Management of Adverse Events of Ipilimumab Including Combination Therapy with Nivolumab].
Uhara H; Itakura E
Gan To Kagaku Ryoho; 2019 Jun; 46(6):1017-1026. PubMed ID: 31273168
[TBL] [Abstract][Full Text] [Related]
10. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S
J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630
[TBL] [Abstract][Full Text] [Related]
11. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
[TBL] [Abstract][Full Text] [Related]
12. Complete Metabolic Response to Combined Immune Checkpoint Inhibition after Progression of Metastatic Colorectal Cancer on Pembrolizumab: A Case Report.
Krekeler C; Wethmar K; Mikesch JH; Kerkhoff A; Menck K; Lenz G; Schildhaus HU; Wessolly M; Hoffmann MW; Pascher A; Asmus I; Wardelmann E; Bleckmann A
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569431
[TBL] [Abstract][Full Text] [Related]
13. Safety of Combination Immune Checkpoint Inhibitors Compared to Monotherapy; A Systematic Review and Meta-Analysis.
Abdelhafeez AAM; Shohdy KS; Ibrahim W
Cancer Invest; 2020 Mar; 38(3):150-157. PubMed ID: 31977260
[TBL] [Abstract][Full Text] [Related]
14. Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab.
Saibil SD; Bonilla L; Majeed H; Sotov V; Hogg D; Chappell MA; Cybulsky M; Butler MO
Curr Oncol; 2019 Jun; 26(3):e418-e421. PubMed ID: 31285688
[TBL] [Abstract][Full Text] [Related]
15. Fatal myositis and spontaneous haematoma induced by combined immune checkpoint inhibitor treatment in a patient with pancreatic adenocarcinoma.
Liu Y; Liu Z; Zeng X; Bai C; Chen L; Lin S; Tian X
BMC Cancer; 2019 Dec; 19(1):1193. PubMed ID: 31805889
[TBL] [Abstract][Full Text] [Related]
16. Restoring Immune Mediated Disease Control by Ipilimumab Re-exposition in a Heavily pretreated Patient With MSI-H mCRC.
Jordan F; Trepel M; Claus R
Clin Colorectal Cancer; 2022 Sep; 21(3):e148-e151. PubMed ID: 35094943
[TBL] [Abstract][Full Text] [Related]
17. A Case of a Pathological Complete Response to Neoadjuvant Nivolumab plus Ipilimumab in Periampullary Adenocarcinoma.
Pothuri V; Herndon J; Ballentine SJ; Lim KH; Fields RC
Oncologist; 2021 Sep; 26(9):722-726. PubMed ID: 33982365
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency.
Cohen R; Pellat A; Boussion H; Svrcek M; Lopez-Trabada D; Trouilloud I; Afchain P; André T
Bull Cancer; 2019 Feb; 106(2):137-142. PubMed ID: 30327191
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O
Morano F; Raimondi A; Pagani F; Lonardi S; Salvatore L; Cremolini C; Murgioni S; Randon G; Palermo F; Antonuzzo L; Pella N; Racca P; Prisciandaro M; Niger M; Corti F; Bergamo F; Zaniboni A; Ratti M; Palazzo M; Cagnazzo C; Calegari MA; Marmorino F; Capone I; Conca E; Busico A; Brich S; Tamborini E; Perrone F; Di Maio M; Milione M; Di Bartolomeo M; de Braud F; Pietrantonio F
J Clin Oncol; 2022 May; 40(14):1562-1573. PubMed ID: 35258987
[TBL] [Abstract][Full Text] [Related]
20. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
Hodi FS; Chesney J; Pavlick AC; Robert C; Grossmann KF; McDermott DF; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor DR; Salama AK; Taylor MH; Ott PA; Horak C; Gagnier P; Jiang J; Wolchok JD; Postow MA
Lancet Oncol; 2016 Nov; 17(11):1558-1568. PubMed ID: 27622997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
